

October 8, 2008



## BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth

NEW HAVEN, Conn., Oct. 8 /PRNewswire/ -- BioXcel Corporation today announced the appointment of three distinguished biopharma executives to its Corporate Advisory Board (CAB). R. Christopher Seaton, SVP of Global Transactions, Bayer Healthcare, Martha Matteo, Ph.D., Past President of SCIP and recently retired from Boehringer Ingelheim Pharmaceuticals, Inc., where she was the Director for Knowledge Management, and Kevin Rakin, Chairman and CEO of Advanced BioHealing, Inc., are known throughout the biopharma world as outstanding and highly experienced pharmaceutical professionals.

BioXcel, a global, business/IP analytics company, will work closely with these industry leaders to design and develop new strategies for its next phase of corporate growth -- targeted to the pharmaceutical, biotechnology, medical device, diagnostic, investment, legal, and related support industries.

"We are delighted to be associated with such a high caliber of experienced pharmaceutical executives," said Vimal D. Mehta, Chairman and co-founder of BioXcel. "Their presence on BioXcel's CAB will assure our planned corporate growth and development at every point in our business model -- from assisting clients with R&D services to all the commercial challenges facing today's complex global industries. BioXcel's senior management, executives, and staff join me in welcoming Christopher, Martha, and Kevin to our valued advisor group. With their advice and guidance, BioXcel is now positioned to achieve our next level of planned business growth, maturity, and service capabilities."

About BioXcel Corporation (<http://www.bioxccl.com>)

Headquartered in New Haven, CT, BioXcel offers business analytics and intellectual property services to the healthcare sector, life science companies, and related industries worldwide. BioXcel's unique, hybrid delivery model capitalizes on US-based expertise and the BioXcel Analytical and Commercial Center (BACC) in India. This "on-shore/off-shore model" leverages highly flexible analytics teams (MS, MTech, PhDs, MDs, Patent Agents, and MBAs) to provide quality services with outstanding breadth and depth.

For additional information, contact:

Krishnan Nandabalan, Ph.D.  
1.203.458.1435  
[knandabalan@bioxccl.com](mailto:knandabalan@bioxccl.com)

This release was issued through eReleases(TM). For more information, visit <http://www.ereleases.com>.

SOURCE BioXcel Corporation